Longevity & Aging
cellular NAD+ improves nuclear-mitochondrial communication
In plain terms: Does falling NAD+ (a key cell-fuel molecule) disrupt how cells power themselves as we age?
Leans against Longevity & Aging 🔬 Includes disconfirming
Part of: • Aging
RefutedContestedStrong support
consensus score -0.49
No — it held in mice, but human trials that raised the molecule showed no benefit.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
3 support 4 contradict 1 tested null 0 mixed · 8 sources, 7 independent groups
What the evidence shows
Sinclair's Gomes-2013 mechanism: age-related NAD+ DECLINE induces a pseudohypoxic HIF-1a state disrupting nuclear-mitochondrial OXPHOS communication. Real in mice; independent human RCTs that raised muscle NAD did NOT reproduce the predicted mitochondrial rescue.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Remie CME, Roumans KHM, Moonen MPB, Connell NJ, Havekes B, Mevenkamp J, Lindeboom L, de Wit VHW, van de Weijer T, Aarts SABM, Lutgens E, Schomakers BV, Elfrink HL, Zapata-Pérez R, Houtkooper RH, Auwerx J, Hoeks J, Schrauwen-Hinderling VB, Phielix E, Schrauwen P 2020 · Am J Clin Nutr | RCT | contradicts | moderate | Independent human RCT: NR raised muscle acetylcarnitine but did not improve mitochondrial/metabolic function as the mechanism predicts |
| Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG 2019 · Cell Rep | RCT | contradicts | high | NR raised aged-muscle NAD+ metabolome but did NOT alter mitochondrial bioenergetics; downregulated mito pathways - predicted human mito benefit absent. |
| Dollerup OL, Chubanava S, Agerholm M, Søndergård SD, Altıntaş A, Møller AB, Høyer KF, Ringgaard S, Stødkilde-Jørgensen H, Lavery GG, Barrès R, Larsen S, Prats C, Jessen N, Treebak JT 2020 · J Physiol | RCT | contradicts | moderate | Independent human RCT: 12wk NR did not alter muscle NAD metabolites, mitochondrial respiration, content or morphology |
| Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA 2013 · Cell | animal | supports | moderate | Mouse + myoblast mechanism study (Sinclair lab): lowering nuclear NAD+ (NMNAT1 knockdown, lactate) stabilised HIF-1a and specifically reduced mitochondrially encoded OXPHOS, mtDNA and ATP; NMN 500 mg/kg/day IP for 1 week in 22-month-old mice reversed HIF-1a accumulation and raised ATP, COX activity and mtDNA-encoded OXPHOS transcripts, SIRT1- and EglN1-dependently ('raising NAD + levels in old mice restores mitochondrial function'). Direction: NAD+ SUSTAINS nuclear-mitochondrial communication; its decline disrupts it - the opposite of the SPO 'cellular NAD+ attenuates' it. No muscle-strength improvement (data not shown). |
| Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P, D'Amico D, Ropelle ER, Lutolf MP, Aebersold R, Schoonjans K, Menzies KJ, Auwerx J 2016 · Science | animal | supports | high | NAD+ repletion (NR) restored mitochondrial function & muscle stem-cell rejuvenation and extended lifespan in aged mice, supporting the NAD->mito-communication mechanism. |
| Ahmadi A, Begue G, Valencia AP, Norman JE, Lidgard B, Bennett BJ, Van Doren MP, Marcinek DJ, Fan S, Prince DK, Gamboa J, Himmelfarb J, de Boer IH, Kestenbaum BR, Roshanravan B 2023 · JCI Insight | RCT | contradicts | moderate | Crossover RCT, 25 CKD patients, NR 1,000 mg/d 6 weeks: no VO2peak or work-efficiency gain vs placebo (VO2peak 21.38 vs 20.64 mL/kg/min, P=0.36), while 'NR supplementation significantly altered TCA cycle intermediates' that use NAD+ as cofactor; authors say NR 'improved markers of systemic mitochondrial metabolism'. NAD+ and nuclear-mitochondrial signalling not measured - off-scope for this mechanism claim. |
| Whitson JA, Bitto A, Zhang H, Sweetwyne MT, Coig R, Bhayana S, Shankland EG, Wang L, Bammler TK, Mills KF, Imai SI, Conley KE, Marcinek DJ, Rabinovitch PS 2020 · Aging Cell | animal | supports | moderate | NMN normalized age-related cardiac energetic (PCr/ATP) decline and increased NAD+ under workload in old mouse hearts, supporting NAD-dependent mito communication. |
| Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR 2018 · Nat Commun | RCT | tested-null | moderate | Chronic NR raised NAD+ and was well tolerated but produced no broad physiological/mitochondrial benefit; only a suggestive BP/arterial-stiffness signal. |
| Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N 2018 · Am J Clin Nutrition | RCT | contradicts | high | 12wk NR in obese insulin-resistant men: no improvement in insulin sensitivity, mitochondrial or metabolic parameters despite NAD+ precursor delivery. |
| Dollerup OL, Trammell SAJ, Hartmann B, Holst JJ, Christensen B, Møller N, Gillum MP, Treebak JT, Jessen N 2019 · J Clin Endocrinol Metab | RCT | contradicts | moderate | NR in nondiabetic men with obesity did not affect beta-cell/alpha-cell function or incretin secretion; predicted NAD/SIRT1 metabolic benefit not seen. |
| Chen F, Zhou D, Kong AP, Yim NT, Dai S, Chen YN, Hui LL 2024 · Current Diabetes Reports | meta-analysis | contradicts | moderate | Meta-analysis of 8 NMN RCTs: no significant benefit on fasting glucose, insulin, HbA1c, HOMA-IR or lipids - human metabolic effect of raising NAD+ unsupported. |
| Prokopidis K, Moriarty F, Bahat G, McLean J, Church DD, Patel HP 2025 · J Cachexia Sarcopenia Muscle | meta-analysis | contradicts | moderate | Meta-analysis: NMN/NR showed no significant effect on muscle mass index, grip strength or gait speed in older adults - predicted muscle/mito benefit absent. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.